论文部分内容阅读
目的探讨Bcl-2和HNF-3β在非小细胞肺癌中的表达及其临床意义。方法应用免疫组化法检测65例非小细胞肺癌和癌旁正常肺组织中HNF-3β和Bcl-2的表达。结果 65例非小细胞肺癌中,Bcl-2和HNF-3β阳性表达率分别为78.5%(51/65)和33.8%(22/65),癌旁正常肺组织Bcl-2和HNF-3β阳性表达率分别为16.9%(11/65)和84.6%(55/65);非小细胞肺癌组织中HNF-3β阳性表达率显著低于癌旁正常肺组织,Bcl-2阳性表达率显著高于癌旁正常肺组织,HNF-3β和Bcl-2蛋白表达呈负相关(P<0.05);HNF-3β低表达和Bcl-2高表达与非小细胞肺癌TNM临床分期、病理组织类型、有无淋巴结转移及患者生存期呈显著相关(P<0.05或<0.01)。结论HNF-3β和Bcl-2在非小细胞肺癌的发生、发展过程中起了重要作用,推测HNF-3β和Bcl-2蛋白表达可共同作为非小细胞肺癌早期诊断、预后评估生物标志物,可作为肺癌预后的一个适用新靶点。
Objective To investigate the expression and clinical significance of Bcl-2 and HNF-3β in non-small cell lung cancer. Methods Immunohistochemistry was used to detect the expression of HNF-3β and Bcl-2 in 65 cases of non-small cell lung cancer and adjacent normal lung tissues. Results The positive rates of Bcl-2 and HNF-3β in 65 patients with NSCLC were 78.5% (51/65) and 33.8% (22/65) respectively. Positive Bcl-2 and HNF-3β were found in para-tumor normal lung tissues. The expression rates were 16.9% (11/65) and 84.6% (55/65) respectively. The positive expression rate of HNF-3β in non-small cell lung cancer tissues was significantly lower than that in normal lung tissues. The positive expression rate of Bcl-2 was significantly higher than that in non-small cell lung cancer tissues. There was a negative correlation between the expression of HNF-3β and Bcl-2 protein in normal lung tissue adjacent to cancer (P<0.05). The low expression of HNF-3β and high expression of Bcl-2 was associated with the clinical stage, pathological type, and presence or absence of TNM in non-small cell lung cancer. Lymph node metastasis and patient survival were significantly correlated (P<0.05 or <0.01). Conclusion HNF-3β and Bcl-2 play important roles in the development of non-small cell lung cancer. It is speculated that the expression of HNF-3β and Bcl-2 may be used as biomarkers for early diagnosis and prognosis assessment of non-small cell lung cancer. It can be used as a new target for the prognosis of lung cancer.